+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 20 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.

Age: 18Years +All GendersPhase 3
563 locations
C

Actively Recruiting

Researchers are evaluating two forms of buprenorphine treatment for Veterans with moderate to severe opioid use disorder OUD. The study compares a long-acting injectable buprenorphine given every 28 days with the standard daily sublingual buprenorphine. This open-label, randomized trial involves 952 Veterans over a 7-year recruitment period and follows them actively for 52 weeks, with additional passive follow-up for up to 10 years. The study also examines effects on substance use, overdose rates, infectious disease status, psychiatric symptoms, housing, dental health, and cost-effectiveness. Participants are first inducted on daily sublingual buprenorphine following SAMHSA guidelines. After reaching a target dose between 4 and 32 mg within 45 days, they are randomized 11 to either continue daily sublingual doses or receive a monthly injectable buprenorphine dose of 300 mg or 100 mg if needed. Study visits occur weekly for the first month, then every two weeks up to week 52, with medication management provided at each visit. Both treatments are administered under clinical supervision with dosing adjustments as needed. Throughout the study, participants complete self-reported opioid use and provide urine samples biweekly. Researchers collect data on retention in treatment, opioid abstinence, overdose events, infectious disease testing, healthcare utilization, craving, psychiatric symptoms, criminal justice involvement, and dental quality of life. After one year of active participation, administrative records are reviewed for ongoing outcomes for up to 10 years. This comprehensive monitoring aims to provide long-term insights into treatment effectiveness and patient well-being.

Age: 18Years +All GendersPhase 4
25 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of eloralintide in adults who are obese or overweight but do not have type 2 diabetes. This Phase 3 clinical trial aims to understand how eloralintide affects body weight and other health measures over time in this population. Participants will be randomly assigned to receive one of four different doses of eloralintide or a placebo, all given by subcutaneous injection. The main phase of the study lasts about 75 weeks, and participants with prediabetes may continue into an extension phase for an additional 2 years to further assess long-term effects. During the study, participants will have regular visits for assessments including body weight, body fat, waist circumference, blood pressure, blood tests, and questionnaires on overall health. Researchers will monitor changes from baseline up to week 64 and longer for some measures, including the time to develop type 2 diabetes. Safety and medication use will also be tracked throughout the study period.

Age: 18Years +All GendersPhase 3
158 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of AlloNK, a non-genetically modified allogeneic natural killer NK cell therapy derived from cord blood, combined with rituximab, in people with relapsing forms of B-cell dependent rheumatologic diseases. These diseases include refractory rheumatoid arthritis, Sjgrens disease, idiopathic inflammatory myopathies, and systemic sclerosis. This open-label Phase 2a study aims to explore treatment options for patients whose conditions have not responded well to previous therapies. Participants receive AlloNK after a conditioning regimen, followed by rituximab. AlloNK is an off-the-shelf, cryopreserved NK cell therapy given in combination with rituximab. The treatment period lasts up to 104 weeks, during which participants are monitored for safety and clinical response. The study includes one treatment group receiving this combination therapy. Throughout the study, participants undergo regular assessments to evaluate safety from enrollment until the end of treatment at Week 104. Researchers measure disease-specific outcomes at Week 52, including disease activity scores for rheumatoid arthritis, Sjgrens disease activity indices, improvement scores for inflammatory myopathies, and response indices for systemic sclerosis. The study involves clinical evaluations, laboratory tests including inflammatory markers, and joint assessments to monitor treatment effects and safety over the extended period.

Age: 18Years +All GendersPhase 2
52 locations
T

Actively Recruiting

Healthy Volunteer

Hearing loss significantly affects emotional well-being, cognition, and physical health, especially in rural populations where access to audiologists and otolaryngologists is limited. This research evaluates a new approach to improve hearing healthcare access by educating pharmacy technicians in rural Alabama and Mississippi to assist adults with mild-to-moderate hearing loss using over-the-counter hearing aids OTC HAs. The study aims to develop a sustainable collaborative care model between audiologists and pharmacists to enhance hearing healthcare availability and affordability in underserved rural areas. Pharmacy technicians will undergo a stepped-wedge educational training program consisting of four sequential steps over 16 weeks no training, online learning modules, online discussions, and practical hands-on experience including hearing screenings and OTC HA adjustments. Adults with hearing loss in these rural areas will receive care from trained technicians and report their satisfaction and experience with OTC HAs. This design allows assessment of both technician training effectiveness and patient outcomes. Participants will be involved in training sessions, practical clinics, and surveys assessing knowledge, confidence, and satisfaction. Adults with hearing loss will complete questionnaires on hearing handicap and hearing aid benefit before and after four weeks of using OTC HAs. The study will measure training impact through quizzes and confidence ratings over the 16-week training period. This trial will support advancing hearing healthcare delivery models and improving quality of life for people with hearing loss in rural communities.

Age: 18Years +All GendersPhase Not Applicable
2 locations
C

Actively Recruiting

Researchers are evaluating two different therapies aimed at improving emotion regulation in autistic adolescents and young adults. The study compares a widely used treatment for non-autistic groups, called The Unified Protocol UP, with a program designed specifically for autistic individuals, called The Emotion Awareness and Skills Enhancement Program EASE. Both therapies target mental health challenges like depression, irritability, and anxiety, which are important issues identified by patients and caregivers. This trial is conducted in partnership with community clinics in Pennsylvania and Alabama to support real-world application. The trial includes two treatment groups one receiving the EASE program and the other receiving the UP therapy. EASE is a 16-session mindfulness-based program focusing on awareness of emotional arousal, distress tolerance, helpful thoughts, and self-compassion. Each session lasts 45 to 60 minutes and is delivered one-on-one, with caregiver involvement encouraged. UP consists of 16 cognitive behavioral therapy sessions, also lasting about 45 to 60 minutes each, focusing on recognizing emotions and developing coping strategies. Each community clinic involved is randomly assigned to provide either EASE or UP. Participants will attend sessions over about 16 to 20 weeks, with assessments at the start, midpoint, end of treatment, and three months after treatment ends. Researchers will measure emotion regulation, mental health symptoms, quality of life, mindfulness, self-compassion, and therapeutic alliance using various questionnaires and scales. The study also evaluates how acceptable and feasible each therapy is for providers and clients. The total participation includes these treatment and follow-up periods, with ongoing monitoring of provider confidence over four years.

Age: 10Years - 30YearsAll GendersPhase Not Applicable
2 locations
C

Actively Recruiting

Researchers are evaluating the effectiveness and safety of oral metformin compared to injectable insulin in treating gestational diabetes mellitus GDM in pregnant individuals. This phase 4, randomized controlled trial aims to determine whether metformin is not worse than insulin in reducing adverse pregnancy outcomes and to assess patient-reported experiences and long-term safety for both mothers and their children. The study involves 1,572 pregnant individuals with GDM requiring medication, recruited from 20 U.S. sites, with follow-up through delivery and up to two years postpartum. Participants are randomly assigned to one of two treatment groups the metformin group or the insulin group. Those in the metformin group will take oral metformin tablets, either immediate- or extended-release, up to a maximum daily dose of 2,500 mg, with insulin added if needed due to insufficient blood sugar control or intolerance. The insulin group will receive injectable insulin, which may include basal and prandial insulins, with dosing adjusted by trimester and weight, following clinical standards. Treatments reflect usual clinical practice, and the trial is open-label without masking. Throughout the study, participants and their children will be monitored with evaluations including pregnancy outcomes, neonatal health, and child growth up to two years of age. Assessments will include maternal health measures such as hypertensive disorders, weight gain, delivery method, and metabolic profiles, as well as child body mass index and other growth indicators. Patient-reported outcomes will be collected at six weeks and two years postpartum. Safety and treatment satisfaction will be tracked, with data collected during routine care and scheduled follow-up visits.

Age: 18Years +FEMALEPhase 4
26 locations
T

Actively Recruiting

Healthy Volunteer

This research aims to evaluate an Interactive Digital PrEP Toolkit designed to help cisgender women in Alabama and Mississippi learn about and access pre-exposure prophylaxis PrEP, a medication that prevents HIV infection. The study focuses on addressing barriers such as limited PrEP awareness, low HIV risk perception, and challenges in client-provider communication, especially in rural southeastern U.S. regions where PrEP use among women remains low. Participants will use the Digital PrEP Toolkit on a tablet during a clinic visit, which includes educational content tailored to women and information about various PrEP options, such as daily pills and injections. After using the Toolkit, participants receive a Personalized HIV Prevention Summary and discuss PrEP options with healthcare staff. Those interested can schedule a PrEP clinic appointment. Follow-up includes phone interviews at 3 months and medical record reviews at 3 and 6 months to assess PrEP uptake and persistence. Participants will be involved in a 30-minute enrollment visit including consent and baseline assessments, use of the Digital PrEP Toolkit, and follow-up interviews. Researchers will evaluate feasibility by measuring Toolkit completion rates and time, acceptability through satisfaction surveys, and preliminary efficacy by tracking PrEP initiation and knowledge changes. Medical records will be reviewed up to 6 months post-enrollment to monitor ongoing PrEP use, with total study participation lasting up to 18 months.

Age: 18Years +FEMALEPhase Not Applicable
4 locations
B

Actively Recruiting

Healthy Volunteer

Researchers are exploring the effects of Sudarshan Kriya Yoga SKY, a type of breath-based meditation, on the well-being of university students. This pilot study will involve 56 undergraduate and graduate students who will be randomly assigned to either a SKY breathwork group or a control group practicing general yoga without breathwork. The study aims to evaluate recruitment success, participant retention, adherence, and potential benefits in areas such as stress, anxiety, resilience, social connection, and cognitive focus. The research is intended to lay groundwork for larger future studies and provide early insights on SKYs role in student wellness. The SKY group will participate in a three-day in-person retreat followed by weekly virtual meditation sessions and independent home practice over eight weeks. The control group will receive pre-recorded yoga videos to practice at least three times per week and occasional check-ins. Both groups will be monitored throughout the study to compare adherence and experience with their assigned activities. Participants will complete validated mental health and wellness questionnaires, including measures of perceived stress, anxiety, physical activity, resilience, and social connectedness before and after the eight-week program. Data will be analyzed for all enrolled participants regardless of completion. The study includes monitoring of physical activity levels and aims to assess the feasibility and low-risk nature of SKY breath meditation for improving student well-being.

Age: 18Years +All GendersPhase Not Applicable
1 location
S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the impact of geriatric evaluation and management combined with survivorship health education GEM-S compared to usual care on physical function in older cancer survivors. This phase III trial aims to improve how older adults who have survived cancer manage daily activities, mental well-being, and memory after chemotherapy. The study also seeks to understand how such care affects the quality of life for both cancer survivors and their caregivers. Participants are assigned to one of two groups based on their practice site. One group receives routine follow-up care from their doctors over three visits within six months. The other group takes part in a one-hour GEM consultation discussing geriatric assessment results and recommendations, attends survivorship health education sessions twice weekly for four weeks, and participates in a daily walking and resistance exercise program called EXCAP. Both survivors and their caregivers are involved in these activities. Throughout the study, participants complete patient-reported assessments on physical and cognitive function, objective tests like a 6-minute walk and cognitive exams, and questionnaires about satisfaction with care and coordination. Caregiver distress and quality of life are also measured. Follow-up continues for six months after the interventions to monitor outcomes and gather data on the effects of the GEM-S approach.

Age: 18Years +All GendersPhase 3
45 locations

1-10 of 20

1